targeted protein degradation resources

TPD Drug Discovery Resources

Links to a range of publicly available resources to assist in drug discovery from target identification, molecule optimisation and competitor landscaping

Targeted Protein Degradation (TPD) company directory

Also now including other Induced Proximity & Bifunctional Therapeutics-Focused Companies - now at 78 and still growing

Have only included companies whose main or only focus is TPD or bifunctional molecule development. There is a lot of great TPD work going on within pharma but that is specifically excluded from this list 

 

  • 76Bio
  • A-Alpha Bio
    • https://www.aalphabio.com/
      • Expanding synthetic biology platform into glue discovery based on huge PPI database from nearly 1Bn datapoints using yeast fusion screening
  • Accutar Biotech
  • Ambagon Therapeutics 
  • Amphista Therapeutics
  • Apertor Pharmaceuticals
  • Arvinas
  • Asha Therapeutics
    • https://www.ashatherapeutics.com/
      • De novo drug design using PRISM (Proximity-inducing small molecules) platform applied to inhibitors, glues and other protein degraders though few specifics
  • AUTOTAC Bio
    • http://autotacbio.com/
      • Korea-based autophagy-based company recruiting p62 receptor into AUTOTACs. Check out Dr Kwon's video on the web site.
  • Automera
  • Avilar Therapeutics
  • Biohaven Therapeutics
    • https://www.biohaven.com/
      • Pre-clinical work on ASGPR-based bivalent degraders (MoDE platform targeting eg IgG or IgA) and antibody-recruiting cytotoxics (ARM platform) including former work from Kleo Pharmaceuticals
  • BioTheryx
  • Booster Therapeutics
  • C4 Therapeutics
  • Captor Therapeutics
  • Casma Therapeutics
  • Celeris
  • Cullgen
  • Dialectic Therapeutics
    • https://www.dtsciences.com/
      • Single asset company with DT2216 in clinic as a VHL-based, platelet-sparing Bcl-xL degrader with claimed improved window over thrombocytopenia relative to Bcl-xL inhibitors like venetoclax due to low VHL expression in platelets
  • Degron Therapeutics
  • Differentiated Therapeutics
  • DraupnirBio
  • Dunad Therapeutics
    • https://www.dunadtx.com/
      • New monovalent inhibitors and degraders using covalent expertise from the labs of founder Pat Gunning
  • EntactBio
    • https://entactbio.com/
      • Komander, Urbe, Buhrlage et al spinout Inducing proximity to deubiquitinases to trim Ub chains to induce protein stabilisation, signalling etc
  • EpiBiologics
  • f5 Therapeutics
  • Fimecs
  • FireflyBio
    • https://fireflybiologics.com/
      • From the Versant team who bought you Mone Rosa comes another ADC meets TPD biotech with Nobelist Carolyn B on board - what's not to love?
  • Foghorn Therapeutics
    • https://foghorntx.com/
      • Range of glues and PROTACs directed to targets in chromatin regulation, now in clinical phase
  • Frontier Medicines
  • Gandeeva Therapeutics
    • https://gandeeva.com/
      • The usual mix of AI to give new glues through proprietary means but with an added dose of cryo-EM to assist in optimisation
  • GluBio Therapeutics
  • GlycoEra
    • https://www.glycoera.com/
      • Extracellular degrader company using bifunctional glycosylated biologics (G-LyTACs) to direct to lysosomal degradation
  • Halda Therapeutics
    • https://haldatx.com/
      • Not TPD but another "CrewsCo" with an unusual take on tying up essential proteins selectively in tumor cells to kill them using RIPTACs
  • Haisco Pharmaceutical Group
  • Hinova Pharmaceutical
  • Indupro Therapeutics
  • Kesmalea Therapeutics
    • https://kesmalea.com/
      • Unique chemistry platform to generate new degrading drugs overcoming problems of first generation agents
  • Kintor Pharmaceutical
  • Kymera
    • https://www.kymeratx.com/
      • Established clinical phase PROTAC company showing progress outside oncology through immunology pipeline
  • Lycia
  • Lyterian
    • https://lyterian.com/
      • Recent entrant to protein homeostasis founded by great team including Ingrid Wertz & Miche Rape
  • Magnet Biomedicines
    • https://magnetbio.com/
      • Rockstar glue company founded by Schreiber, Cravatt et al promising rational glue discovery using their TrueGlue platform
  • Monte Rosa
  • Neomorph
  • NeoX
  • Nested Therapeutics
    • https://nestedtx.com/
      • Now in clinic with lead asset NST-628, a non-degrading molecular glue which sticks MEK to different RAF isoforms thus inhibiting MAPK signalling with broad anti-tumor effects.
  • Nurix
  • Oerth.bio
    • https://www.oerthbio.com/
      • Joint venture between Arvinas & Bayer to apply TPD methods to agri applications though presumably will need ultra high potency to keep cost of good down and won't be spraying IMiD derivatives on fields?
  • Orionis Biosciences
  • Origami Therapeutics
    • https://origamitherapeutics.com/
      • Claim to have platform able to identify protein stabilizers and degraders though are setting sights high by focusing on CNS targets
  • Orum Therapeutics
    • https://www.orumrx.com/
      • Leading degrader-antibody conjugate company using mainly GSPT1 glue conjugates also in protein stabilisation via E3 inhibitors
  •  Outrun Therapeutics
    • https://outruntx.com/
      • April 2024 spinout from Satpal Virdee at Dundee aims to inhibit specific E3 ligases for selective protein stabilization
  • Paq Therapeutics
  • Phoremost
  • Photys
  • Pin Therapeutics
  • Plexium
  • Progenra
    • https://progenra.com/
      • PROTAC and glue company now pivoted to focus on Parkinson's Disease via Parkin/PINK axis
  • Proteovant
    • https://proteovant.com/ - now acquired by SK Biopharmaceuticals
      • Former TPD-focused Vant from the Roivant family previously advancing the Oncopia TPD pipeline from Shaomeng Wang
  • Proxidrugs
    • https://www.proxidrugs.de/
      • Not a biotech as such but a cluster of German universities, led out of Frankfurt, focused on therpaeutic application of TPD
  • Proxygen
  • Ranok Therapeutics
    • https://www.ranoktherapeutics.com/
      • Enigmatic TPD company advancing unique chaperone-recruiting mechanism to degrade protein with claimed tumor-specific effects. Now in clinic - unique mechanism throws up many opportunities and questions.
  • Rapafusyn Pharmaceuticals
  • Salarius Pharmaceuticals
  • Seed Therapeutics
  • Sibylla Biotech
    • https://www.sibyllabiotech.it/
      • A novel protein degradation strategy from Italy acting on folding intermediates rather than mature protein. Interesting.
  • Siduma Therapeutics
    • https://www.sidumathera.com/
      • Still stealthy but led by Craig Crews and some of the original Arvinas crowd so expect to see some interesting bifunctional-based efficacy - or maybe not this time. Closed April 2024
  • Solu Therapeutics
    • https://solutherapeutics.com/
      • Modulating the immune system by bifunctional antibody-recruiting CyTaCs (Cytotoxicity Targeting Chimera) using a nice approach spun out of GSK
  • Stablix
    • https://www.stablix.com/
      • Recruiting deubiquitinases to stabilize proteins in the antithesis to PROTACs. Likely to be useful for many loss of function disorders if as flexible as TPD
  • SyntheX
    • https://www.synthexlabs.com/
      • Machine learning to find glues to specific E3 ligases. 2022 deal with BMS who know a thing or two about glue discovery.
  • Triana Biosciences
  • Ubiquigent
  • Ubix
  • Uppthera
  • Venquis
  • Vicinitas
  •  
  • Civetta, Cedilla, Polyprox (no longer trading)

NB Monovalent degraders are often called molecular glues, MonoDACs, CELMods, NEXMods etc

Bifunctional degraders were initially known as PROTACs but this is now a trademarked term (by Arvinas) so proteolysis-targeting chimeras may be known as BiDACs, Proximity-Inducing Compounds etc

I will call bifunctional degraders PROTAC(TM)s here and acknowledge Arvinas' trademark

 

For a directory of upcoming TPD conferences, please click here

TPD Drug Discovery Resources

  • Want to know everything about the localisaton of your drug target of choice? Head over to the Human Protein Atlas
  • A concise summary of a wealth of CRISPR & RNAi screens is held at DepMap. There's a shiny app visualisation to help show targets required for tumor cell proliferation or cell essentiality.
  • For a record of most active and complete clinical studies, please visit Clinicaltrials.gov
  • See the great range of resources collated by Chris Swain at Cambridge Med Chem Consulting for help on everything from hit identification through to lead optimisation and candidate selection
  •  
  • For commentary on recent important literature in the TPD space, take a look at the CeTPD Journal Club, run by members of Alessio Ciulli's team from the Centre for TPD at the University of Dundee
  • Some good links to cheat sheets and other general drug discovery info can be found from DrugHunter here 
  • More resources being added all the time - check back soon

 

We need your consent to load the translations

We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.